TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00776724
Drug: E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8.
Study: NCT00507091
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT00945425
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule, once or twice daily, 7 days
Study: NCT00945425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule, once or twice daily, 7 days
Study: NCT02728622
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel or pegylated liposomal doxorubicin
Study: NCT04250922
Drug: LAM561
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment.
Study: NCT01047670
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
Study: NCT00393354
Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00393354
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03708848
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT03708848
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT01638364
Drug: alcoholic beverage
Normalized name: Alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
Study: NCT02183142
Drug: Mobic, China, 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183142
Drug: Mobic, Germany, 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733316
Drug: RP103
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733316
Drug: Cystagon®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01333033
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01333033
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00646789
Drug: Comparator: MK0633
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
Study: NCT00659750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01558739
Drug: INC424
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
Study: NCT00947011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 100 mg once a day
Study: NCT01475188
Drug: Allergovit
Approvals — FDA: no, EMA: no, PMDA: no
Description: commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
Study: NCT01135290
Drug: HP828-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02717273
Drug: extended
Normalized name: Extended Tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: extended three-day course of antibiotics
Study: NCT03764085
Drug: Rheosorbilact®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Study: NCT03764085
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study: NCT00802087
Drug: hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended Release tablet
Study: NCT00802087
Drug: hydrocodone & acetaminophen combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release tablet, hydrocodone and acetaminophen combination product
Study: NCT00500409
Drug: Osteoform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
Study: NCT00500409
Drug: SHELCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
Study: NCT04037566
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
Study: NCT00804609
Drug: DepoDur following spinal anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug.
Study: NCT00132509
Drug: NINDS
Normalized name: The full generic name for the drug abbreviation 'NINDS' is not readily available. NINDS stands for the National Institute of Neurological Disorders and Stroke, which is a division of the National Institutes of Health (NIH) in the United States. It is not a drug or medication name.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase : 0.9mg/kg over 60 minutes
Study: NCT03561753
Drug: Group A (the standard 2HRZE/4HR regimen）
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
Study: NCT03561753
Drug: Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Study: NCT02305888
Drug: LEO 43204
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of actinic keratosis
Study: NCT04526509
Drug: GSK3901961
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3901961 as an IV infusion.
Study: NCT02008110
Drug: Standard treatment strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
Study: NCT03588390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to low strength tablet
Study: NCT03588390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to middle strength tablet
Study: NCT03588390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to high strength tablet
Study: NCT00603343
Drug: Mictonetten 5 mg, coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
Study: NCT00603343
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo corresponding to body weight
Study: NCT01164033
Drug: RO5045337
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT04526509
Drug: GSK3845097
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3845097 as an IV infusion.
Study: NCT04526509
Drug: GSK4427296
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4427296 as an IV infusion.
Study: NCT04526509
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study: NCT01266096
Drug: PET scan with 124I-cRGDY-PEG-dots
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
Study: NCT04421547
Drug: Standard single agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
Study: NCT03567057
Drug: ADS-5102, 274 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT00631111
Drug: effervescent ibuprofen tablets
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00631111
Drug: effervescent Aspirin plus Vitamin C tablets
Normalized name: aspirin Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00631111
Drug: ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00631111
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03820193
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03820193
Drug: Hydrocodon/Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditionally used narcotic pain control
Study: NCT03820193
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03820193
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT01189864
Drug: Ciprofloxicin or Vigamox or other.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
Study: NCT01189864
Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
Study: NCT03778229
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to osimertinib (oral OD)
Study: NCT03672500
Drug: Bupivacaine 0.5%+Epinephrine 50mc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
Study: NCT00892242
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02631928
Drug: human biphasic insulin, reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
Study: NCT02586857
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
Study: NCT04297501
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
Study: NCT05070520
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
Study: NCT04657484
Drug: Medium dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Same as arm description
Study: NCT04657484
Drug: Low dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Same as arm description
Study: NCT00358826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosing, 1 time daily for 12 or 24 weeks
Study: NCT00167674
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
Study: NCT01420783
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT04053478
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine, at applicable concentrations based on literature
Study: NCT03999125
Drug: Ozurdex Drug Implant Product
Normalized name: Ozurdex Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
Study: NCT00000372
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00670475
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
Study: NCT03822962
Drug: Ibuprofen 600Mg Tablet
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
Study: NCT01077206
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg daily versus 40mg daily, for 21 days.
Study: NCT00210626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40,000 IU/mL/week for max of 12 weeks
Study: NCT01227668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 16 weeks
Study: NCT03846271
Drug: intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an identical amount of placebo nasal spray will be applied to each subject.
Study: NCT00939133
Drug: tretinoin microsphere 0.04% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied daily to entire face for six months
Study: NCT00939133
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01211769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
Study: NCT04158258
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study: NCT01513668
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release Gel tabs 650 mg
Study: NCT02416258
Drug: Daivobet® gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04528173
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
Study: NCT04528173
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
Study: NCT02862210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
Study: NCT03161028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
Study: NCT03001609
Drug: AC0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
Study: NCT00667927
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT00756964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
Study: NCT04403100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets - 01 tablet twice daily from day 01 through day 10.
Study: NCT01533428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Patch
Study: NCT00882895
Drug: Solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02984683
Drug: SAR566658 (ACT14884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study: NCT03118739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally, once daily for 24 weeks
Study: NCT02231320
Drug: Berodual® Respimat® - inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01323998
Drug: 5ARI
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride or Finasteride
Study: NCT01544114
Drug: VIMOVO 250/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Study: NCT01544114
Drug: VIMOVO 375/20
Normalized name: Vimovo 375/20 Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Study: NCT01544114
Drug: VIMOVO 500/20
Normalized name: Vimovo 500/20 Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Study: NCT03519867
Drug: Zemuron®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
Study: NCT01946204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Study: NCT01429402
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
Study: NCT01429402
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
Study: NCT00798070
Drug: FEC→T
Normalized name: Fluorouracil, Epirubicin, and Cyclophosphamide followed by Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
Study: NCT00382018
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration details available